头孢他啶-阿维巴坦对碳青霉烯类耐药和产超毒力肺炎克雷伯菌的活性。
Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates.
机构信息
Department of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Department of Laboratory Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
出版信息
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.01031-18. Print 2018 Aug.
Abstract
Carbapenem-resistant and hypervirulent (CR-hvKp) strains have emerged while antimicrobial treatment options remain limited. Herein, we tested the activity of ceftazidime-avibactam and other comparator antibiotics against 65 CR-hvKp isolates. Ceftazidime-avibactam, colistin, and tigecycline are highly active against CR-hvKp isolates (MIC, ≤1 μg/ml), including carbapenemase 2 (KPC-2)-producing ST11 CR-hvKp. On the basis of previous clinical experience and the data presented herein, we posit that ceftazidime-avibactam is a therapeutic option against CR-hvKp infections.
摘要
耐碳青霉烯和超毒力 （CR-hvKp） 菌株的出现，而抗菌治疗选择仍然有限。在此，我们测试了头孢他啶-阿维巴坦和其他比较抗生素对 65 株耐碳青霉烯和超毒力 （CR-hvKp） 分离株的活性。头孢他啶-阿维巴坦、黏菌素和替加环素对 CR-hvKp 分离株具有高度活性（MIC，≤1μg/ml），包括产碳青霉烯酶 2 （KPC-2）的 ST11 CR-hvKp。基于先前的临床经验和本文提供的数据，我们假设头孢他啶-阿维巴坦是治疗 CR-hvKp 感染的一种治疗选择。
相似文献
1
Activity of Ceftazidime-Avibactam against Carbapenem-Resistant and Hypervirulent Klebsiella pneumoniae Isolates.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.01031-18. Print 2018 Aug.
2
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
3
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5.
4
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
5
Emergence of Hypervirulent ST11-K64 Poses a Serious Clinical Threat in Older Patients.
Front Public Health. 2022 Mar 4;10:765624. doi: 10.3389/fpubh.2022.765624. eCollection 2022.
6
ARGONAUT-III and -V: susceptibility of carbapenem-resistant and multidrug-resistant to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
Antimicrob Agents Chemother. 2024 Sep 4;68(9):e0075124. doi: 10.1128/aac.00751-24. Epub 2024 Aug 12.
7
Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent .
Emerg Microbes Infect. 2024 Dec;13(1):2361007. doi: 10.1080/22221751.2024.2361007. Epub 2024 Jun 12.
8
A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Isolated in New York City.
mSphere. 2020 Aug 26;5(4):e00775-20. doi: 10.1128/mSphere.00775-20.
9
Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent .
Virulence. 2024 Dec;15(1):2348251. doi: 10.1080/21505594.2024.2348251. Epub 2024 May 2.
10
Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
Microb Drug Resist. 2018 Jan/Feb;24(1):35-39. doi: 10.1089/mdr.2016.0293. Epub 2017 Jun 7.
引用本文的文献
1
Hypervirulent : Insights into Virulence, Antibiotic Resistance, and Fight Strategies Against a Superbug.
Pharmaceuticals (Basel). 2025 May 15;18(5):724. doi: 10.3390/ph18050724.
2
Molecular Characterization and Risk Factors of Carbapenem-Resistant Hypervirulent Isolated from Chinese Tertiary Hospital.
Infect Drug Resist. 2025 Jan 6;18:83-92. doi: 10.2147/IDR.S494208. eCollection 2025.
3
Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent .
Virulence. 2024 Dec;15(1):2348251. doi: 10.1080/21505594.2024.2348251. Epub 2024 May 2.
4
Isolation and characterization of three novel lytic phages against K54 serotype carbapenem-resistant hypervirulent .
Front Cell Infect Microbiol. 2023 Dec 12;13:1265011. doi: 10.3389/fcimb.2023.1265011. eCollection 2023.
5
Virulence factors in carbapenem-resistant hypervirulent .
Front Microbiol. 2023 Nov 30;14:1325077. doi: 10.3389/fmicb.2023.1325077. eCollection 2023.
6
activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent isolates.
Microbiol Spectr. 2023 Dec 12;11(6):e0280623. doi: 10.1128/spectrum.02806-23. Epub 2023 Nov 20.
7
Carbapenem-Resistant : Virulence Factors, Molecular Epidemiology and Latest Updates in Treatment Options.
Antibiotics (Basel). 2023 Jan 21;12(2):234. doi: 10.3390/antibiotics12020234.
8
Global spread and evolutionary convergence of multidrug-resistant and hypervirulent high-risk clones.
Pathog Glob Health. 2023 Jun;117(4):328-341. doi: 10.1080/20477724.2022.2121362. Epub 2022 Sep 11.
9
Ceftazidime-avibactam based combinations against carbapenemase producing harboring hypervirulence plasmids.
Comput Struct Biotechnol J. 2022 Jul 15;20:3946-3954. doi: 10.1016/j.csbj.2022.07.017. eCollection 2022.
10
Emergence of Hypervirulent ST11-K64 Poses a Serious Clinical Threat in Older Patients.
Front Public Health. 2022 Mar 4;10:765624. doi: 10.3389/fpubh.2022.765624. eCollection 2022.
本文引用的文献
1
Genome analysis of clinical multilocus sequence Type 11 Klebsiella pneumoniae from China.
Microb Genom. 2018 Feb;4(2). doi: 10.1099/mgen.0.000149. Epub 2018 Feb 8.
2
Antimicrobial Resistance of Hypervirulent : Epidemiology, Hypervirulence-Associated Determinants, and Resistance Mechanisms.
Front Cell Infect Microbiol. 2017 Nov 21;7:483. doi: 10.3389/fcimb.2017.00483. eCollection 2017.
3
Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.
mBio. 2017 Oct 31;8(5):e00528-17. doi: 10.1128/mBio.00528-17.
4
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783.
5
A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study.
Lancet Infect Dis. 2018 Jan;18(1):37-46. doi: 10.1016/S1473-3099(17)30489-9. Epub 2017 Aug 29.
6
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00883-17. Print 2017 Aug.
7
Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes?
Virulence. 2017 Oct 3;8(7):1111-1123. doi: 10.1080/21505594.2017.1317412. Epub 2017 Apr 12.
8
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02097-16. Print 2017 Mar.
9
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20.
10
Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study.
Lancet Infect Dis. 2016 Feb;16(2):161-8. doi: 10.1016/S1473-3099(15)00424-7. Epub 2015 Nov 19.
Zotero 插件